Skip to main content
Nitin Vaishampayan, MD, Radiation Oncology, Detroit, MI

NitinGangadharVaishampayanMD

Radiation Oncology Detroit, MI

Physician

Dr. Vaishampayan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Vaishampayan's full profile

Already have an account?

  • Office

    4100 John R St
    Gershenson Radiation Oncology CTR
    Detroit, MI 48201
    Phone+1 800-527-6266
    Fax+1 313-576-9640

Summary

  • Dr. Nitin Vaishampayan is a radiation oncologist based in Detroit, MI with a notable teaching role at Karmanos Cancer Center. His medical education started at University of Michigan, followed by an internship and residencies at Wayne State University School of Medicine and Detroit Medical Center/Wayne State University respectively. Having specialized in Radiation Oncology, he has made substantial contributions to medical literature, with numerous well-cited publications in recognized journals on topics ranging from Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer, pediatric myeloid sarcoma to the prognostic value of ratio changes in cervical cancer patients.

Education & Training

  • Detroit Medical Center/Wayne State University
    Detroit Medical Center/Wayne State UniversityResidency, Radiation Oncology, 1992 - 1996
  • Wayne State University School of Medicine
    Wayne State University School of MedicineInternship, Transitional Year, 1991 - 1992
  • University of Michigan Medical School
    University of Michigan Medical SchoolClass of 1991

Certifications & Licensure

  • MI State Medical License
    MI State Medical License 1996 - 2027
  • American Board of Radiology Radiation Oncology

Publications & Presentations

PubMed

Press Mentions

  • Post-ASCO News Alert: Novartis’ Lu-PSMA Early Uptake in Castration-Resistant Prostate Cancer May Be Stalled by Radiopharmaceutical Logistic Issues, Though Approvable
    Post-ASCO News Alert: Novartis’ Lu-PSMA Early Uptake in Castration-Resistant Prostate Cancer May Be Stalled by Radiopharmaceutical Logistic Issues, Though ApprovableJune 25th, 2021